- Current report filing (8-K)
November 09 2009 - 6:04AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of Earliest Event Reported):
November 9,
2009
AVI
BioPharma, Inc.
(Exact name of
registrant as specified in its charter)
Oregon
|
|
001-14895
|
|
93-0797222
|
(State or other
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
|
jurisdiction of
|
|
|
|
Identification No.)
|
incorporation)
|
|
|
|
|
3450
Monte Villa Parkway, Suite 101
Bothell,
WA 98021
(Address of
principal executive offices)
(425)
354-5038
Registrants
telephone number, including area code
(Former name or
former address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
o
|
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02. Results of Operations and Financial
Condition.
On November 9, 2009, AVI BioPharma, Inc.
(the Company) issued a press release announcing the Companys financial
results for the third fiscal quarter ended September 30, 2009. A copy of the press release is attached as Exhibit 99.1
to this Current Report on Form 8-K.
The information in this Item 2.02, in
Item 9.01 hereof and in Exhibit 99.1 shall not be deemed to be
filed for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
The following exhibit is being furnished (not filed)
herewith:
99.1
|
Press release, dated November 9, 2009, entitled
AVI BioPharma Announces Third Quarter 2009 Financial Results & Corporate
Highlights
|
2
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of
the Securities Exchange Act of 1934, as amended, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Bothell, State of Washington, on November 9,
2009.
|
AVI BioPharma, Inc.
|
|
|
|
By:
|
/s/ Leslie Hudson, Ph.D.
|
|
|
|
|
|
Leslie Hudson, Ph.D.
|
|
|
President and Chief Executive
Officer
(Principal Operating Officer)
|
3
EXHIBIT
INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press release, dated November 9, 2009, entitled
AVI BioPharma Announces Third Quarter 2009 Financial Results & Corporate
Highlights
|
4
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024